hero

Compa Community Jobs

Discover open compensation roles across our Compa Index community network
Hero Box Icon

VP and Above

View Roles
Hero Box Icon

Senior and Director roles

View Roles
Hero Box Icon

Entry Level

View Roles
companies
Jobs
Showing 308 companies
Activision Blizzard
Activision Blizzard

Activision Blizzard’s mission is to connect and engage the world through epic entertainment. One of the successful interactive entertainment companies, its franchises include popular games like Call of Duty®, Warcraft® (Warcraft®, World of Warcraft®, Hearthstone®), Overwatch®, Diablo®, StarCraft®, Candy Crush™, Crash Bandicoot™, Guitar Hero®, Tony Hawk's™ Pro Skater™, Bubble Witch™, Pet Rescue™, Farm Heroes™, and Spyro™. Through these franchises, the company reaches more than 400 million players across 190 countries. Activision Blizzard’s business units and development studios include Activision Publishing, Blizzard Entertainment, King Games, Infinity Ward, Raven Software, Sledgehammer Games, Treyarch Studios, Beenox, Demonware, High Moon Studios, and Toys for Bob. The company supports corporate social responsibility initiatives that are directly tied to its franchises. As an example, the Call of Duty Endowment has helped find employment for over 100,000 veterans. Bobby Kotick currently serves as Chief Executive Officer of Activision Blizzard. He became CEO of Activision in 1991 after purchasing a company stake the previous year. Kotick engineered a merger between Activision and Vivendi Games during the late 2000s, which led to the creation of Activision Blizzard in 2008 and his being named the company's inaugural CEO. Activision Blizzard is a member of the Fortune 500 and the S&P 500. Activision Blizzard has been recognized as one of FORTUNE magazine's “100 Best Companies To Work For.”

Alnylam Pharmaceuticals
Alnylam Pharmaceuticals
1 jobs

To those who say “impossible, impractical, unrealistic,” we say: “Challenge accepted.” Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring RNAi-based medicines to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious, and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Alnylam is turning scientific possibility into reality - in 2018, the FDA and EMA approved our first product, Onpattro (patisiran), which is also the first-ever approved RNAi therapeutic. We now have four additional medicines on the market. Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of 2,000+ people. We pride ourselves on fostering a fun, inclusive, and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Science magazine Top Employer 5 years in a row ('19-'23), a Boston Globe Top Place to Work 9x in a row ('15-'23), and Fast Company's #1 Best Workplace for Innovators ('22). We are based in Cambridge, U.S., with offices throughout Europe, Asia, and South America.